Rigel Pharmaceuticals (RIGL) – Analysts’ Weekly Ratings Updates

Rigel Pharmaceuticals (NASDAQ: RIGL) has recently received a number of price target changes and ratings updates:

• 8/25/2026 – Rigel Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 8/17/2026 – Rigel Pharmaceuticals had its “neutral” rating reaffirmed by Piper Sandler. They now have a $49.00 price target on the stock, up from $40.00.
• 8/17/2026 – Rigel Pharmaceuticals was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/14/2026 – Rigel Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $85.00 price target on the stock, up from $57.00.
• 8/6/2026 – Rigel Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 8/6/2026 – Rigel Pharmaceuticals had its “buy” rating reaffirmed by Citigroup Inc..
• 7/17/2026 – Rigel Pharmaceuticals had its “hold (c+)” rating reaffirmed by Weiss Ratings.

Insider Activity

In related news, Director Kamil Ali-Jackson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.00, for a total transaction of $87,500.00. Following the completion of the sale, the director directly owned 10,125 shares in the company, valued at approximately $354,375. This trade represents a 19.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.47% of the company’s stock.

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).